(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 43.79% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 123.12%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Eton Pharmaceuticals's revenue in 2025 is $49,422,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2025 to be $2,147,306,845, with the lowest ETON revenue forecast at $2,049,476,477, and the highest ETON revenue forecast at $2,227,866,720. On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $3,024,213,422, with the lowest ETON revenue forecast at $2,693,821,391, and the highest ETON revenue forecast at $3,496,738,389.
In 2027, ETON is forecast to generate $3,940,032,242 in revenue, with the lowest revenue forecast at $3,335,028,653 and the highest revenue forecast at $4,816,161,111.